S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   436.85 (+0.36%)
AAPL   180.02 (-0.77%)
MSFT   407.69 (+-0.01%)
META   486.19 (+0.45%)
GOOGL   136.79 (+0.30%)
AMZN   174.60 (+0.83%)
TSLA   199.97 (-1.02%)
NVDA   789.83 (+1.70%)
NIO   5.64 (+3.87%)
AMD   186.13 (+5.43%)
BABA   74.25 (-0.46%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.54 (-0.19%)
CGC   3.31 (-1.49%)
GE   155.91 (+0.19%)
DIS   111.40 (+0.54%)
AMC   4.43 (-11.22%)
PFE   26.79 (-0.92%)
PYPL   60.24 (-0.02%)
XOM   104.83 (+0.49%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   436.85 (+0.36%)
AAPL   180.02 (-0.77%)
MSFT   407.69 (+-0.01%)
META   486.19 (+0.45%)
GOOGL   136.79 (+0.30%)
AMZN   174.60 (+0.83%)
TSLA   199.97 (-1.02%)
NVDA   789.83 (+1.70%)
NIO   5.64 (+3.87%)
AMD   186.13 (+5.43%)
BABA   74.25 (-0.46%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.54 (-0.19%)
CGC   3.31 (-1.49%)
GE   155.91 (+0.19%)
DIS   111.40 (+0.54%)
AMC   4.43 (-11.22%)
PFE   26.79 (-0.92%)
PYPL   60.24 (-0.02%)
XOM   104.83 (+0.49%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   436.85 (+0.36%)
AAPL   180.02 (-0.77%)
MSFT   407.69 (+-0.01%)
META   486.19 (+0.45%)
GOOGL   136.79 (+0.30%)
AMZN   174.60 (+0.83%)
TSLA   199.97 (-1.02%)
NVDA   789.83 (+1.70%)
NIO   5.64 (+3.87%)
AMD   186.13 (+5.43%)
BABA   74.25 (-0.46%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.54 (-0.19%)
CGC   3.31 (-1.49%)
GE   155.91 (+0.19%)
DIS   111.40 (+0.54%)
AMC   4.43 (-11.22%)
PFE   26.79 (-0.92%)
PYPL   60.24 (-0.02%)
XOM   104.83 (+0.49%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   436.85 (+0.36%)
AAPL   180.02 (-0.77%)
MSFT   407.69 (+-0.01%)
META   486.19 (+0.45%)
GOOGL   136.79 (+0.30%)
AMZN   174.60 (+0.83%)
TSLA   199.97 (-1.02%)
NVDA   789.83 (+1.70%)
NIO   5.64 (+3.87%)
AMD   186.13 (+5.43%)
BABA   74.25 (-0.46%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.54 (-0.19%)
CGC   3.31 (-1.49%)
GE   155.91 (+0.19%)
DIS   111.40 (+0.54%)
AMC   4.43 (-11.22%)
PFE   26.79 (-0.92%)
PYPL   60.24 (-0.02%)
XOM   104.83 (+0.49%)
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$5.44
-0.08 (-1.45%)
(As of 12:03 PM ET)
Today's Range
$5.36
$5.62
50-Day Range
$5.24
$6.21
52-Week Range
$1.24
$6.30
Volume
898,459 shs
Average Volume
1.32 million shs
Market Capitalization
$1.67 billion
P/E Ratio
90.67
Dividend Yield
N/A
Price Target
$5.40

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
2.2% Downside
$5.40 Price Target
Short Interest
Healthy
1.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Amneal Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.04%
From $0.49 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

640th out of 958 stocks

Pharmaceutical Preparations Industry

308th out of 450 stocks


AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

6 reasons to buy Teva Pharmaceuticals stock sooner than later (AMRX)
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Here's what to expect from Amneal Pharmaceuticals A's earnings report
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Amneal to Participate at Upcoming Investor Conference
Top 3 Pharma Stocks With Bullish Momentum
Knight Therapeutics Inks License Agreement With Amneal Pharma For IPX203
Amneal Announces Move to Nasdaq
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/05/2023
Today
2/29/2024
Next Earnings (Confirmed)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.40
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-2.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.37 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
225,126,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
1.34
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives















AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

5 brokerages have issued twelve-month target prices for Amneal Pharmaceuticals' shares. Their AMRX share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.40 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the beginning of 2024. Since then, AMRX shares have decreased by 9.1% and is now trading at $5.52.
View the best growth stocks for 2024 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a drop in short interest in February. As of February 15th, there was short interest totaling 2,100,000 shares, a drop of 17.3% from the January 31st total of 2,540,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.9% of the shares of the stock are sold short.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our AMRX earnings forecast
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, March 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its earnings results on Friday, May, 5th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.01. The business earned $557.54 million during the quarter, compared to analyst estimates of $555 million. Amneal Pharmaceuticals had a net margin of 0.43% and a trailing twelve-month return on equity of 109.82%. During the same quarter in the prior year, the company earned $0.10 earnings per share.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY23 earnings guidance on Wednesday, January, 10th. The company provided earnings per share (EPS) guidance of $0.51-0.58 for the period, compared to the consensus estimate of $0.59. The company issued revenue guidance of $2.37-2.42 billion, compared to the consensus revenue estimate of $2.41 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.45%), Rubric Capital Management LP (2.61%), Dimensional Fund Advisors LP (0.92%), Nantahala Capital Management LLC (0.76%), Nuveen Asset Management LLC (0.64%) and Charles Schwab Investment Management Inc. (0.43%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 2/29/2024 by MarketBeat.com Staff